GlaxoSmithKline Pharmaceuticals on Friday said it has registered a consolidated net profit of Rs 156.51 crore for the third quarter ended December.
The company had reported a net loss of Rs 661.16 crore in the October-December period of 2019-20.
Revenue from operations rose by 10 per cent to Rs 857.20 crore during the third quarter as against Rs 778.59 crore in the year-ago period, the company said in a regulatory filing.
"The company demonstrated a strong rebound with sales growing by 33 per cent from first quarter of FY21 post a decline in the pandemic peak, as most of our key brands gained market share and outpaced their competitor brands," GlaxoSmithKline Pharmaceuticals MD Sridhar Venkatesh said.
Vaccines and respiratory segments remain important growth areas for the company and are expected to grow in higher double digits, he added.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.